Fig. 5: Serum troponin T increase occurred post–ABBV-467 infusion. | Communications Medicine

Fig. 5: Serum troponin T increase occurred post–ABBV-467 infusion.

From: Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

Fig. 5

Serum troponin T release occurred post–ABBV-467 infusion. Representative graph of serum troponin T levels from a single patient on ABBV-467 during cycle 1 of treatment. Troponin T elevations were first identified after the patient received their first full dose of ABB-467. Troponin T remained elevated throughout the first cycle with values ranging from 0.015 to 0.038 ng/mL. Arrows represent the days the patient received ABB-467 (Dash = ½ target dose, Solid = target dose). Target dose = 0.53 mg/kg Q1W. (Reference range: ≤0.014 ng/mL). Q1W, once per week.

Back to article page